Umbilical cord-derived Wharton's jelly for regenerative medicine applications
- PMID: 32054483
- PMCID: PMC7017504
- DOI: 10.1186/s13018-020-1553-7
Umbilical cord-derived Wharton's jelly for regenerative medicine applications
Abstract
Background: The last decade has seen an explosion in the interest in using biologics for regenerative medicine applications, including umbilical cord-derived Wharton's Jelly. There is insufficient literature assessing the amount of growth factors, cytokines, hyaluronic acid, and extracellular vesicles including exosomes in these products. The present study reports the development of a novel Wharton's jelly formulation and evaluates the presence of growth factors, cytokines, hyaluronic acid, and extracellular vesicles including exosomes.
Methods: Human umbilical cords were obtained from consenting caesarian section donors. The Wharton's jelly was then isolated from the procured umbilical cord and formulated into an injectable form. Randomly selected samples from different batches were analyzed for sterility testing and to quantify the presence of growth factors, cytokines, hyaluronic acid, and extracellular vesicles.
Results: All samples passed the sterility test. Growth factors including IGFBP 1, 2, 3, 4, and 6, TGF-α, and PDGF-AA were detected. Several immunomodulatory cytokines, such as RANTES, IL-6R, and IL-16, were also detected. Pro-inflammatory cytokines MCSFR, MIP-1a; anti-inflammatory cytokines TNF-RI, TNF-RII, and IL-1RA; and homeostatic cytokines TIMP-1 and TIMP-2 were observed. Cytokines associated with wound healing, ICAM-1, G-CSF, GDF-15, and regenerative properties, GH, were also expressed. High concentrations of hyaluronic acid were observed. Particles in the extracellular vesicle size range were also detected and were enclosed by the membrane, indicative of true extracellular vesicles.
Conclusion: There are numerous growth factors, cytokines, hyaluronic acid, and extracellular vesicles present in the Wharton's jelly formulation analyzed. The amount of these factors in Wharton's jelly is higher compared with other biologics and may play a role in reducing inflammation and pain and augment healing of musculoskeletal injuries.
Keywords: Biologics; Exosomes; Growth factors, cytokines; Hyaluronic acid; Musculoskeletal injuries; Osteoarthritis; Regenerative medicine; Umbilical cord; Wharton’s jelly.
Conflict of interest statement
AG and SEI are consultants for BioIntegrate LLC. HL and SFE own equity in BioIntegrate LLC.
Figures
![Fig. 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/7017504/bin/13018_2020_1553_Fig1_HTML.gif)
Similar articles
-
Absence of Wharton's Jelly at the Abdominal Site of the Umbilical Cord Insertion. Rare Case Report and Review of the Literature.Medicina (Kaunas). 2021 Nov 18;57(11):1268. doi: 10.3390/medicina57111268. Medicina (Kaunas). 2021. PMID: 34833486 Free PMC article. Review.
-
Umbilical cord-derived Wharton's jelly for treatment of knee osteoarthritis: study protocol for a non-randomized, open-label, multi-center trial.J Orthop Surg Res. 2021 Feb 18;16(1):143. doi: 10.1186/s13018-021-02300-0. J Orthop Surg Res. 2021. PMID: 33602286 Free PMC article. Clinical Trial.
-
Umbilical cord-derived Wharton's jelly for regenerative medicine applications in orthopedic surgery: a systematic review protocol.J Orthop Surg Res. 2020 Nov 11;15(1):527. doi: 10.1186/s13018-020-02067-w. J Orthop Surg Res. 2020. PMID: 33176838 Free PMC article.
-
Exosomes from acellular Wharton's jelly of the human umbilical cord promotes skin wound healing.Stem Cell Res Ther. 2018 Jul 13;9(1):193. doi: 10.1186/s13287-018-0921-2. Stem Cell Res Ther. 2018. PMID: 30005703 Free PMC article.
-
Wharton's Jelly stem cells: future clinical applications.Placenta. 2011 Oct;32 Suppl 4:S311-5. doi: 10.1016/j.placenta.2011.06.010. Epub 2011 Jul 6. Placenta. 2011. PMID: 21733573 Review.
Cited by
-
Safety and Efficacy of Wharton's Jelly Connective Tissue Allograft for Rotator Cuff Tears: Findings from a Retrospective Observational Study.Biomedicines. 2024 Mar 22;12(4):710. doi: 10.3390/biomedicines12040710. Biomedicines. 2024. PMID: 38672066 Free PMC article.
-
Exploring Orthopedic Stem-Cell Approaches for Osteoarthritis Management: Current Trends and Future Horizons.Curr Pain Headache Rep. 2024 Jan;28(1):27-35. doi: 10.1007/s11916-023-01191-6. Epub 2023 Nov 27. Curr Pain Headache Rep. 2024. PMID: 38010488 Review.
-
Drug Delivery of Gelatin Nanoparticles as a Biodegradable Polymer for the Treatment of Infectious Diseases: Perspectives and Challenges.Polymers (Basel). 2023 Nov 5;15(21):4327. doi: 10.3390/polym15214327. Polymers (Basel). 2023. PMID: 37960007 Free PMC article. Review.
-
Human umbilical cord mesenchymal stem cells promoting knee joint chondrogenesis for the treatment of knee osteoarthritis: a systematic review.J Orthop Surg Res. 2023 Aug 29;18(1):639. doi: 10.1186/s13018-023-04131-7. J Orthop Surg Res. 2023. PMID: 37644595 Free PMC article.
-
Innovations in cell therapy in pediatric diseases: a narrative review.Transl Pediatr. 2023 Jun 30;12(6):1239-1257. doi: 10.21037/tp-23-92. Epub 2023 Jun 9. Transl Pediatr. 2023. PMID: 37427072 Free PMC article. Review.
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous